Introduction
This report provides a comprehensive analytics report of the publisher American Society of Clinical Oncology (ASCO) including basic bibliometric information, citation data, impact metrics, top journals, publication keywords, etc., over recent years. The Crossref database (up to the end of 2021) processed by ScienceGate has been used for this report as the source of data.
American Society of Clinical Oncology (ASCO) has published 141283 documents so far, receiving a total of 2421860 citations. These numbers are equal to 0.12% and 0.22% of the total documents and citations in the scientific community, respectively. American Society of Clinical Oncology (ASCO) has a score of 17.14 as a number of citations per document based on all recorded data. There are different types of documents published by American Society of Clinical Oncology (ASCO). In this regard, Journal Article, Dataset, and Other a with the total document number of 140240, 1042, and 1 have the largest share, respectively. These numbers are equal to 99.26%, 0.74%, and 0.00% of the total documents published in American Society of Clinical Oncology (ASCO) so far, respectively. American Society of Clinical Oncology (ASCO) has been an active publisher from 1983-2021.
Basic Bibliometric Information
This section provides the bibliometrics data of American Society of Clinical Oncology (ASCO) over the last 11 years, including the number of published documents, total citations, citations per document, and scaled number of citations per document by year. Share of American Society of Clinical Oncology (ASCO) documents and citations among all published scientific documents are also presented here. American Society of Clinical Oncology (ASCO) has the highest annual number of publications in 2018, with 10006 published documents. Most annual citations are also received in 2010, with 132148 citations. The highest citations per document’s scores, scaled by the number of years ahead, are associated with 2020, with scores of 0.73.
Year | Documents | Citations | Citations/Documents | Average Citations/Documents | Documents Share | Citations Share |
---|---|---|---|---|---|---|
2010 | 6050 | 132148 | 21.8426 | 1.9857 | 0.0017 | 0.0032 |
2011 | 7057 | 106757 | 15.1278 | 1.5128 | 0.0018 | 0.0026 |
2012 | 7736 | 90262 | 11.6678 | 1.2964 | 0.0019 | 0.0023 |
2013 | 7464 | 82774 | 11.0898 | 1.3862 | 0.0017 | 0.0022 |
2014 | 7841 | 65325 | 8.3312 | 1.1902 | 0.0017 | 0.0019 |
2015 | 7814 | 68376 | 8.7504 | 1.4584 | 0.0016 | 0.0022 |
2016 | 8563 | 55733 | 6.5086 | 1.3017 | 0.0016 | 0.0020 |
2017 | 8634 | 47174 | 5.4637 | 1.3659 | 0.0015 | 0.0021 |
2018 | 10006 | 35367 | 3.5346 | 1.1782 | 0.0017 | 0.0021 |
2019 | 8764 | 17710 | 2.0208 | 1.0104 | 0.0014 | 0.0018 |
2020 | 9244 | 6734 | 0.7285 | 0.7285 | 0.0013 | 0.0020 |
Document Types
There are different types of documents published by publishers. In this section, the yearly publication data of American Society of Clinical Oncology (ASCO) are presented by document type, including Journal Articles, and Datasets.
The number of published documents by American Society of Clinical Oncology (ASCO) are 140240, and 1042 for Journal Articles, and Datasets, respectively. These numbers are equal to 0.15%, and 0.05% of the whole published Journal Articles, and Datasets in the database so far, respectively.
The number of received citations by Journal Articles, and Datasets of American Society of Clinical Oncology (ASCO) are 2421857, and 3, respectively. These numbers are equal to 0.23%, and 0.00% of the citations received by whole Journal Articles, and Datasets of the database so far, respectively.
The h-index value for published Journal Articles, and Datasets by American Society of Clinical Oncology (ASCO) are 513, and 1, respectively. The corresponding values for the whole data of the database are 3201, and 98, respectively.
The g-index value for published Journal Articles, and Datasets by American Society of Clinical Oncology (ASCO) are 40, and 1, respectively. The corresponding values for the whole data of the database are 129, and 20, respectively.
The score of citations per document for published Journal Articles, and Datasets by American Society of Clinical Oncology (ASCO) are 17.269, and 0.003, respectively. The corresponding values for the whole data of the database are 11.521, and 0.070, respectively.
The highest number of annually published Journal Articles, and Datasets by American Society of Clinical Oncology (ASCO) are 9993, and 328, respectively. The corresponding year of maximum publication for Journal Articles, and Datasets are 2018, and 2019, respectively.
The highest number of annual received citations by Journal Articles, and Datasets published in American Society of Clinical Oncology (ASCO) are 132148, and 3, respectively. The corresponding years of maximum received citations for Journal Articles, and Datasets are 2010, and 2019, respectively.
The highest values of citations per number of document for Journal Articles, and Datasets published in American Society of Clinical Oncology (ASCO) are 21.84, and 0.01, respectively. The corresponding years of maximum values of citations per document for Journal Articles, and Datasets are 2010, and 2019, respectively.
Impact Metrics
Various metrics and indicators are used to evaluate the impact and quality of publishers and journals. Here, h-index, g-index, and i-index are selected as impact evaluation metrics of the publisher American Society of Clinical Oncology (ASCO).
H-index
H-index indicates the number of articles published by a journal/publisher, h, that have been cited at least h times. h5-index and h10-index are the h-index for papers of a publishers/journals published in the last 5 and 10 years, respectively. h-index, h10-index, and h5-index of the documents published by American Society of Clinical Oncology (ASCO), are 513, 285, and 150, respectively. The corresponding values for the whole data of the database are 3269, 1489, and 795, respectively.
Metric | American Society of Clinical Oncology (ASCO) | All Publishers |
---|---|---|
h-index | 513 | 3269 |
h10-index | 285 | 1489 |
h5-index | 150 | 795 |
G-index
The g-index indicator is the first g papers of a publisher/journal (sorted by the highest to the lowest number of citations) that have cumulatively received at least g^2 citations. Again, g5-index and g10-index are the g-index for papers of a publishers/journals published in the last 5 and 10 years, respectively. G-index, g10-index, and g5-index of the documents published by American Society of Clinical Oncology (ASCO) are 40, 28, and 20, respectively. The corresponding values for the whole data of the database are 131, 80, and 55, respectively.
Metric | American Society of Clinical Oncology (ASCO) | All Publishers |
---|---|---|
g-index | 40 | 131 |
g10-index | 28 | 80 |
g5-index | 20 | 55 |
I-n index
I-n index shows the number of publications of a publisher/journal with at least n citations. Read another post here for more detailed information on different research impact metrics. It is to be noted that, i10-index, i25-index, i50-index, i100-index, i250-index, i500-index, i1000-index, i2500-index, i5000-index, and i10000-index of the documents published by American Society of Clinical Oncology (ASCO), are 22323, 16062, 11708, 6922, 2029, 545, 120, 6, 0, and 0, respectively. The corresponding values for the whole data of the database are 21796896, 10617845, 4822066, 1785083, 390499, 114230, 31648, 5505, 1423, and 355, respectively.
Metric | American Society of Clinical Oncology (ASCO) | All Publishers |
---|---|---|
i10-index | 22323 | 21796896 |
i25-index | 16062 | 10617845 |
i50-index | 11708 | 4822066 |
i100-index | 6922 | 1785083 |
i250-index | 2029 | 390499 |
i500-index | 545 | 114230 |
i1000-index | 120 | 31648 |
i2500-index | 6 | 5505 |
i5000-index | 0 | 1423 |
i10000-index | 0 | 355 |
Top Journals
This section provides the basic bibliometrics data of the American Society of Clinical Oncology (ASCO) top journals, including the number of published documents, total citations, and citations per document. Share of documents and citations of each journal among all published documents by American Society of Clinical Oncology (ASCO) is also presented here. In the following tag cloud chart, top journals are displayed based on the largest number of published documents.
The Top 5 journals of American Society of Clinical Oncology (ASCO) based on the number of published documents are Journal of Clinical Oncology, Journal of Oncology Practice, Journal of Global Oncology, American Society of Clinical Oncology Educational Book, and JCO Precision Oncology. The numbers of documents published so far by these top 5 journals are 131740, 2838, 1773, 1327, and 807, respectively. These numbers are equal to 93.245%, 2.009%, 1.255%, 0.939%, and 0.571% of the total documents published by American Society of Clinical Oncology (ASCO) so far, respectively.
Concerning the number of received citations, the top 5 journals of American Society of Clinical Oncology (ASCO) are Journal of Clinical Oncology, Journal of Oncology Practice, American Society of Clinical Oncology Educational Book, JCO Precision Oncology, and Journal of Global Oncology. The total number of citations received so far by these top 5 journals are 131740, 2838, 1327, 807, and 1773, respectively. These numbers are equal to 5.440%, 0.117%, 0.055%, 0.033%, and 0.073% of the total citations received by American Society of Clinical Oncology (ASCO) publications so far, respectively.
Regarding the number of citations received per document, the top 5 journals of American Society of Clinical Oncology (ASCO) are Journal of Clinical Oncology, Journal of Oncology Practice, American Society of Clinical Oncology Educational Book, JCO Precision Oncology, and JCO Clinical Cancer Informatics. The numbers of citations received per published document so far by these top 5 journals are 18.112, 7.866, 5.938, 2.466, and 2.218, respectively.
Journal Title | Documents | Documents Share | Citations | Citations Share | Citations/Documents | Active Years |
---|---|---|---|---|---|---|
Journal of Clinical Oncology | 131740 | 0.9325 | 2386118 | 0.9852 | 18.1123 | 1983-2020 |
Journal of Oncology Practice | 2838 | 0.0201 | 22323 | 0.0092 | 7.8658 | 2005-2019 |
Journal of Global Oncology | 1773 | 0.0125 | 1863 | 0.0008 | 1.0508 | 2015-2019 |
American Society of Clinical Oncology Educational Book | 1327 | 0.0094 | 7880 | 0.0033 | 5.9382 | 2012-2020 |
JCO Precision Oncology | 807 | 0.0057 | 1990 | 0.0008 | 2.4659 | 2017-2020 |
JCO Oncology Practice | 807 | 0.0057 | 342 | 0.0001 | 0.4238 | 2020-2020 |
JCO Global Oncology | 480 | 0.0034 | 303 | 0.0001 | 0.6312 | 2020-2020 |
JCO Clinical Cancer Informatics | 468 | 0.0033 | 1038 | 0.0004 | 2.2179 | 2017-2020 |
Top Keywords
The Most used keywords are of particular importance for reviewing a publisher. This section provides detailed information about basic bibliometrics data of top used keywords in American Society of Clinical Oncology (ASCO). The metrics used here are the number of documents, citations and citations per document. Share of documents and citations of each keyword among whole published documents is also presented here. In the following tag cloud chart, top keywords are displayed based on the largest number of published documents.
According to the number of published documents, the top 10 keywords of the publisher American Society of Clinical Oncology (ASCO) are breast cancer, overall survival, lung cancer, phase ii, clinical trial, cancer patients, prostate cancer, clinical trial information, colorectal cancer, and small cell lung cancer, respectively. The number of published documents in which the mentioned 10 keywords are used are, 18228, 13305, 10514, 9632, 8830, 8250, 8226, 7834, 7465, and 6516, respectively.
Based on the number of received citations, the top 10 keywords of the publisher American Society of Clinical Oncology (ASCO) are overall survival, breast cancer, lung cancer, phase ii, small cell lung cancer, disease free, cell lung cancer, small cell lung, phase iii, and quality of life, respectively. The number of citations received by the documents in which the mentioned 10 keywords are used are, 13305, 18228, 10514, 9632, 6516, 3443, 5922, 5615, 3383, and 4314, respectively.
Concerning the score of received citations per document, the top 10 keywords of the publisher American Society of Clinical Oncology (ASCO) are epidermal growth factor receptor, median survival, growth factor, response rate, high dose, disease free, prognostic factors, free survival, phase iii, and bone marrow, respectively. The score of citations received per document in which the mentioned 10 keywords are used are, 69.643, 59.223, 55.281, 47.694, 45.588, 44.392, 44.136, 42.638, 42.214, and 41.667, respectively.
Keyword | Documents | Documents Share | Citations | Citations Share | Citations/Documents | Active Years | Active Years For All Data |
---|---|---|---|---|---|---|---|
breast cancer | 18228 | 0.0615 | 391682 | 0.0910 | 21.4879 | 1983-2020 | 1880-2020 |
overall survival | 13305 | 0.3034 | 407214 | 0.6200 | 30.6061 | 1983-2020 | 1960-2020 |
lung cancer | 10514 | 0.0659 | 205407 | 0.1021 | 19.5365 | 1983-2020 | 1921-2020 |
phase ii | 9632 | 0.2246 | 191103 | 0.3008 | 19.8404 | 1983-2020 | 1900-2020 |
clinical trial | 8830 | 0.1141 | 94991 | 0.0943 | 10.7578 | 1983-2020 | 1926-2020 |
cancer patients | 8250 | 0.0750 | 95576 | 0.0826 | 11.5850 | 1983-2020 | 1884-2020 |
prostate cancer | 8226 | 0.0623 | 95378 | 0.0506 | 11.5947 | 1983-2020 | 1905-2020 |
clinical trial information | 7834 | 0.9891 | 26590 | 0.9874 | 3.3942 | 2004-2020 | 1991-2020 |
colorectal cancer | 7465 | 0.0773 | 132922 | 0.0945 | 17.8060 | 1983-2020 | 1905-2020 |
small cell lung cancer | 6516 | 0.0883 | 159000 | 0.1571 | 24.4015 | 1983-2020 | 1969-2020 |
phase i | 6326 | 0.1942 | 101598 | 0.2170 | 16.0604 | 1983-2020 | 1909-2020 |
cell lung cancer | 5922 | 0.0794 | 150328 | 0.1461 | 25.3847 | 1983-2020 | 1962-2020 |
small cell lung | 5615 | 0.0739 | 146257 | 0.1387 | 26.0476 | 1983-2020 | 1969-2020 |
small cell | 5262 | 0.0658 | 117286 | 0.1138 | 22.2892 | 1983-2020 | 1875-2020 |
cell carcinoma | 4692 | 0.0379 | 82025 | 0.0583 | 17.4819 | 1983-2020 | 1910-2020 |
clinical trials | 4490 | 0.0596 | 122138 | 0.1115 | 27.2022 | 1983-2020 | 1912-2020 |
quality of life | 4314 | 0.0258 | 139187 | 0.0748 | 32.2640 | 1983-2020 | 1905-2020 |
high risk | 4299 | 0.0431 | 93002 | 0.0839 | 21.6334 | 1983-2020 | 1930-2020 |
first line | 4127 | 0.1476 | 76435 | 0.2698 | 18.5207 | 1985-2020 | 1711-2020 |
adverse events | 3612 | 0.1058 | 88647 | 0.2365 | 24.5424 | 1987-2020 | 1970-2020 |
the impact | 3606 | 0.0081 | 58535 | 0.0166 | 16.2327 | 1984-2020 | 1868-2020 |
disease free | 3443 | 0.2477 | 152840 | 0.5933 | 44.3915 | 1983-2020 | 1901-2020 |
phase iii | 3383 | 0.1953 | 142810 | 0.3831 | 42.2140 | 1983-2020 | 1937-2020 |
free survival | 3161 | 0.1755 | 134780 | 0.5094 | 42.6384 | 1983-2020 | 1965-2020 |
phase ii study | 3113 | 0.2267 | 43507 | 0.2188 | 13.9759 | 1983-2020 | 1969-2020 |
ovarian cancer | 3094 | 0.0588 | 60719 | 0.0827 | 19.6248 | 1983-2020 | 1895-2020 |
grade 3 | 3043 | 0.3889 | 78677 | 0.7240 | 25.8551 | 1985-2020 | 1944-2020 |
solid tumors | 3004 | 0.2027 | 43797 | 0.1754 | 14.5796 | 1983-2020 | 1882-2020 |
locally advanced | 2960 | 0.1215 | 44036 | 0.1806 | 14.8770 | 1983-2020 | 1957-2020 |
renal cell carcinoma | 2869 | 0.0797 | 46257 | 0.1022 | 16.1230 | 1984-2020 | 1952-2020 |
radiation therapy | 2856 | 0.0574 | 104724 | 0.1621 | 36.6681 | 1983-2020 | 1922-2020 |
gastric cancer | 2839 | 0.0511 | 26260 | 0.0412 | 9.2497 | 1984-2020 | 1884-2020 |
pancreatic cancer | 2836 | 0.0675 | 30929 | 0.0531 | 10.9059 | 1983-2020 | 1906-2020 |
metastatic breast cancer | 2610 | 0.1664 | 62052 | 0.2934 | 23.7747 | 1983-2020 | 1955-2020 |
the mean | 2524 | 0.0172 | 42647 | 0.0287 | 16.8966 | 1983-2020 | 1669-2020 |
growth factor | 2509 | 0.0177 | 138701 | 0.0341 | 55.2814 | 1989-2020 | 1921-2020 |
multivariate analysis | 2505 | 0.0922 | 76476 | 0.2081 | 30.5293 | 1983-2020 | 1939-2020 |
lymph node | 2482 | 0.0483 | 53439 | 0.0787 | 21.5306 | 1983-2020 | 1908-2020 |
metastatic colorectal cancer | 2408 | 0.2336 | 52898 | 0.3216 | 21.9676 | 1984-2020 | 1975-2020 |
adjuvant chemotherapy | 2353 | 0.1996 | 58461 | 0.3202 | 24.8453 | 1983-2020 | 1961-2020 |
head and neck | 2339 | 0.0342 | 46198 | 0.0568 | 19.7512 | 1983-2020 | 1781-2020 |
renal cell | 2336 | 0.0602 | 42961 | 0.0844 | 18.3908 | 1984-2020 | 1952-2020 |
prognostic factors | 2286 | 0.0905 | 100894 | 0.2127 | 44.1356 | 1983-2020 | 1916-2020 |
phase ii trial | 2234 | 0.2390 | 35366 | 0.2479 | 15.8308 | 1983-2020 | 1975-2020 |
significant difference | 2227 | 0.0276 | 43422 | 0.1192 | 19.4980 | 1983-2020 | 1923-2020 |
first line treatment | 2193 | 0.1963 | 54788 | 0.3939 | 24.9831 | 1984-2020 | 1969-2020 |
response rate | 2185 | 0.1933 | 104211 | 0.5805 | 47.6938 | 1983-2020 | 1949-2020 |
squamous cell carcinoma | 2151 | 0.0342 | 34280 | 0.0520 | 15.9368 | 1983-2020 | 1910-2020 |
metastatic breast | 2067 | 0.1344 | 48259 | 0.2365 | 23.3474 | 1983-2020 | 1955-2020 |
gene expression | 2049 | 0.0111 | 33304 | 0.0081 | 16.2538 | 1990-2020 | 1900-2020 |
risk factors | 2017 | 0.0098 | 55822 | 0.0200 | 27.6758 | 1983-2020 | 1948-2020 |
squamous cell | 1995 | 0.0282 | 31972 | 0.0403 | 16.0261 | 1983-2020 | 1910-2020 |
t cell | 1981 | 0.0146 | 38454 | 0.0112 | 19.4114 | 1983-2020 | 1953-2020 |
breast cancer patients | 1858 | 0.0729 | 23211 | 0.0909 | 12.4925 | 1986-2020 | 1951-2020 |
bone marrow | 1842 | 0.0179 | 76750 | 0.0377 | 41.6667 | 1983-2020 | 1882-2020 |
stem cell | 1820 | 0.0156 | 54578 | 0.0267 | 29.9879 | 1983-2020 | 1929-2020 |
colon cancer | 1775 | 0.0561 | 33827 | 0.0670 | 19.0575 | 1984-2020 | 1934-2020 |
partial response | 1771 | 0.3639 | 60491 | 0.6676 | 34.1564 | 1983-2020 | 1943-2020 |
high dose | 1759 | 0.0433 | 80189 | 0.1309 | 45.5878 | 1983-2020 | 1936-2020 |
multiple myeloma | 1757 | 0.0445 | 39152 | 0.0729 | 22.2834 | 1983-2020 | 1898-2020 |
log rank test | 1739 | 0.3230 | 32242 | 0.7022 | 18.5405 | 1985-2020 | 1970-2020 |
hepatocellular carcinoma | 1712 | 0.0215 | 19746 | 0.0165 | 11.5339 | 1984-2020 | 1961-2020 |
line treatment | 1709 | 0.1596 | 24949 | 0.2184 | 14.5986 | 1988-2020 | 1948-2020 |
neoadjuvant chemotherapy | 1701 | 0.1296 | 27740 | 0.2111 | 16.3081 | 1984-2020 | 1969-2020 |
in vitro | 1691 | 0.0033 | 25878 | 0.0030 | 15.3034 | 1983-2020 | 1500-2020 |
disease progression | 1668 | 0.0863 | 47829 | 0.1537 | 28.6745 | 1984-2020 | 1948-2020 |
cancer care | 1662 | 0.1784 | 17097 | 0.2410 | 10.2870 | 1991-2020 | 1955-2020 |
health care | 1660 | 0.0092 | 22198 | 0.0166 | 13.3723 | 1986-2020 | 1906-2020 |
line chemotherapy | 1625 | 0.3390 | 24754 | 0.4624 | 15.2332 | 1985-2020 | 1976-2020 |
logistic regression | 1593 | 0.0326 | 18989 | 0.0533 | 11.9203 | 1983-2020 | 1969-2020 |
dose escalation | 1552 | 0.2157 | 20828 | 0.2024 | 13.4201 | 1985-2020 | 1970-2020 |
increased risk | 1543 | 0.0346 | 48693 | 0.0866 | 31.5574 | 1985-2020 | 1950-2020 |
stage iii | 1528 | 0.1786 | 31386 | 0.2908 | 20.5406 | 1983-2020 | 1894-2020 |
palliative care | 1472 | 0.0459 | 15432 | 0.0690 | 10.4837 | 1995-2020 | 1956-2020 |
median survival | 1468 | 0.3374 | 86940 | 0.6471 | 59.2234 | 1983-2020 | 1954-2020 |
early stage | 1461 | 0.0427 | 31063 | 0.0860 | 21.2615 | 1988-2020 | 1827-2020 |
second line | 1452 | 0.1519 | 16235 | 0.2033 | 11.1811 | 1987-2020 | 1810-2020 |
clinical practice | 1429 | 0.0216 | 36529 | 0.0463 | 25.5626 | 1986-2020 | 1905-2020 |
newly diagnosed | 1422 | 0.0685 | 33398 | 0.1357 | 23.4866 | 1983-2020 | 1966-2020 |
over time | 1420 | 0.0164 | 31250 | 0.0372 | 22.0070 | 1985-2020 | 1904-2020 |
phase i study | 1413 | 0.2287 | 15794 | 0.1870 | 11.1776 | 1983-2020 | 1963-2020 |
generation sequencing | 1411 | 0.0642 | 5390 | 0.0235 | 3.8200 | 2010-2020 | 2000-2020 |
cancer survivors | 1409 | 0.0894 | 26169 | 0.1338 | 18.5727 | 1990-2020 | 1956-2020 |
rectal cancer | 1408 | 0.0646 | 26991 | 0.0885 | 19.1697 | 1989-2020 | 1888-2020 |
monoclonal antibody | 1396 | 0.0380 | 48968 | 0.0570 | 35.0774 | 1983-2020 | 1500-2020 |
decision making | 1387 | 0.0074 | 23588 | 0.0152 | 17.0065 | 1984-2020 | 1900-2020 |
united states | 1387 | 0.0043 | 41562 | 0.0133 | 29.9654 | 1984-2020 | 1785-2020 |
side effects | 1376 | 0.0324 | 31235 | 0.0736 | 22.6999 | 1983-2020 | 1892-2020 |
t cells | 1361 | 0.0136 | 18883 | 0.0066 | 13.8744 | 1983-2020 | 1960-2020 |
epidermal growth factor receptor | 1359 | 0.0846 | 94645 | 0.2038 | 69.6431 | 1992-2020 | 1970-2020 |
b cell | 1349 | 0.0215 | 46117 | 0.0375 | 34.1861 | 1983-2020 | 1931-2020 |
patient reported | 1347 | 0.0608 | 18604 | 0.1136 | 13.8114 | 1991-2020 | 1903-2020 |
bladder cancer | 1335 | 0.0407 | 15843 | 0.0417 | 11.8674 | 1984-2020 | 1935-2020 |
median time | 1310 | 0.2229 | 30481 | 0.5049 | 23.2679 | 1983-2020 | 1969-2020 |
real world | 1298 | 0.0216 | 693 | 0.0023 | 0.5339 | 2006-2020 | 1863-2020 |
tumor cells | 1282 | 0.0381 | 20004 | 0.0323 | 15.6037 | 1983-2020 | 1907-2020 |